Evaluating plasma ferritin and suPAR as treatable traits for critically ill patients with COVID-19 treated with anakinra: an exploratory analysis of the immune modulation domain of the REMAP-CAP randomised clinical trial.
Crit CareOct 1, 2026 (epub)
Andrew J Boyle, Elizabeth G Ryan, Lindsay R Berry et al.
✦ AI-curated · Sources linked
In 30 seconds
This exploratory analysis of the REMAP-CAP randomized clinical trial evaluated plasma ferritin and suPAR as potential treatable traits for anakinra in critically ill COVID-19 patients. Among 1243 patients, increasing ferritin levels correlated with fewer organ support-free days (OSFD). In contrast, low baseline suPAR levels were associated with a higher probability of anakinra benefit (94.8% vs. 38.6% for high suPAR).
Key findings
- Patients with increasing ferritin levels had numerically fewer OSFDs.
- Anakinra showed a 94.8% probability of benefit in patients with low baseline suPAR.
- Patients with high baseline suPAR had a 38.6% probability of benefit from anakinra.
Why it matters
Identifying treatable traits in critically ill COVID-19 patients can enhance precision medicine approaches, potentially improving outcomes with targeted therapies like anakinra.